Hwabao WP CSI Medical Service ETF

Norges Bank Increases Stake in Pharmaron by 254,500 Shares, Latest Holding Ratio Reaches 7.07%

HKEX Discloses: JPMorgan Increases Short Position in Wuxi AppTec H-Share to 3.34% on May 14

Hangzhou Topmed to Hold AGM on June 9 to Vote on Special Resolution for A-Share Buyback

JPMorgan Cuts Tigercat Profit Forecasts and Target Price to 39 HKD

BlackRock Increases Stake in Wuxi AppTec H-Shares to 6.32%

Controlling Shareholder Investigated, Tigermed's 1 Billion Buyback Fails to Stop Stock Decline

China Renaissance Global Fund Increases Stake in Tigermed by 719,300 Shares on May 14 for HKD 25.84 Million

Schroders PLC Reduces Stake in Tigermed by 579,300 Shares on May 14

Orient Securities: WuXi AppTec 2026 Q1 Net Profit 4.65B, Maintains Buy Rating with Target Price 140.16 Yuan

Norges Bank Increases Holding of Tigermed to 813,800 Shares

Hangzhou Therapeutic Biotechnology Proposes Up to 100 Million Yuan Stock Repurchase Plan

CSO 实际控制 persons under investigation for disclosure violations related to shareholding changes

Acceleration of Chinese Innovative Drugs Internationalization and Wuxi Biologics' Exceeding Expectations in Q1 2026

BlackRock Reduces Holdings in Kangbok Chemical's H Shares

BlackRock Increases Holding in Wuxi Biologics H Shares

Goldman Sachs Downgrades Taige Pharma's Profit Forecast and Target Price

HSBC Upgrades Wuxi Biologics Rating and Target Price

Three Shareholders of Kanglong Chemical Plan to Reduce 1.57% Equity

China Construction Bank Reiterates Buy Rating on Hangzhou Therasky Medical Consulting's H Shares

00945

159837

516930

516500

512170

LABU

159849

Manulife Singapore will launch the Shield™ multi-cancer detection test in May 2026 through its partnership with Guardant Health, becoming the first in Singapore to offer this blood test for multiple cancers. This initiative supports preventive healthcare, addressing the rising demand for early cancer detection. The Shield™ test has received Breakthrough Device Designation from the FDA and was recognized as Oncology Product Innovation of the Year. Manulife aims to empower customers in managing their health and finances.

Singapore Business Review

Guardant Health

MANULIFE-S

Manulife Financial

Ark Genomic Revolution ETF

E Fund CSI Biotechnology Theme ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Minsheng Royal CSI Biotechnology Theme ETF

VanEck Biotech ETF

ChinaAMC CSI Biotechnology Theme ETF

Direxion S&P Biotech Bull 3X

China Merchants CSI Biotechnology Theme ETF

Direxion S&P Biotech Bear 3X

Manulife Singapore to offer multi-cancer blood test starting May

562600

159898

159883

513060

Boule Diagnostics AB's 2026 AGM approved the 2025 financial statements, decided to retain earnings without a dividend, and granted discharge from liability to the board and CEO. The existing board structure was reaffirmed, reappointing all five directors, including chairman Torben Jørgensen. Shareholders renewed key authorizations for issuing new shares and managing the company's own shares, enhancing Boule's financial flexibility for future capital raising and strategic options. Boule Diagnostics operates in decentralized hematology and diagnostic solutions globally, with a market cap of SEK125.4M.

Tip Ranks

ChinaAMC CSI All Share Health Care Devices ETF

China Merchants CSI All Share Medical Apparatus and Instruments ETF

SPDR S&P Health Equip

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

Bosera Hang Seng Health Care ETF(QDII)

iShares US Medical Devices

Boule Diagnostics AGM Retains Earnings, Renews Board Mandates

02170

Suzhou Basecare Medical Corp. Ltd. has received NMPA Class III approval for its Gems cleavage embryo culture medium, enhancing its portfolio of certified products. This medium, developed with expertise from the Sydney IVF Center, aims to improve embryo stress resistance and support in assisted reproduction. With this approval, all four core products in the Gems series are now certified, creating a comprehensive embryo culture system for fertility specialists. The company focuses on assisted reproductive technologies and has a market cap of HK$506M.

BASECARE-B

Basecare Wins NMPA Class III Approval for Gems Embryo Culture Medium

Imaging Biometrics Limited has corrected an error regarding its proposed share sub-division ahead of the Annual General Meeting on June 3, 2026. Each ordinary share of £0.01 will now be sub-divided into one ordinary share of £0.005, with the total shares remaining at 246,709,789. The AGM resolutions remain unaffected, and updated documentation will be available on the company’s website. Spark’s AI Analyst rates IBAI stock as Neutral, citing weak financial performance and bearish technicals, despite low leverage reducing balance-sheet risk.

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

Proshares UltraShort Nasdaq Biotech

iShares Biotechnology ETF

ALPS Medical Breakthrough

GE HealthCare Tech

Imaging Biometrics Corrects AGM Share Sub-division Terms Ahead of June Meeting

Suzhou Basecare Medical Corp. Ltd. has scheduled its 2025 annual general meeting for June 4, 2026, in Suzhou. Shareholders will review key reports, vote on the 2026 budget, profit distribution, director remuneration, and the re-appointment of KPMG as auditor. They will also consider granting the board mandates for share issuance and repurchase, along with proposed amendments to the Articles of Association. The meeting will include details on proxy voting and the share register closure for H-shareholders.

Suzhou Basecare Calls 2025 AGM to Approve Reports, Budget and Capital Mandates

512290

IBBQ

Alcatraz has announced new platform innovations for its facial biometric authentication system, enhancing device management and user experience. Key updates include real-time audio alerts for authentication events, automatic firmware updates, and consent-based enrollment features. These enhancements aim to improve accessibility, streamline operations, and ensure compliance while maintaining a privacy-first approach. CEO Tina D'Agostin emphasized the company's commitment to reducing friction in security processes. Alcatraz, based in Cupertino, California, serves various sectors, including AI data centers and major enterprises, with over $100 million in capital raised.

prnewswire

Guotai CSI Bio-medicine ETF

iShares US Healthcare Providers

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Invesco Nasdaq Biotechnology ETF

ICBCCS SSE STAR Biology and Medicine ETF

China Universal NASDAQ Biotechnology Technology ETF(QDII)

Health Care Select Sector SPDR

iShares Genomics Immunology and Healthcare ETF

Penghua SSE STAR Biology and Medicine ETF

05:30 ETAlcatraz Simplifies Biometric Enrollment and Device Management with Latest Product Update

The article discusses the potential of AI in revolutionizing cancer detection and its implications for investment. It highlights the importance of early detection in healthcare, citing studies that show significant cost savings and improved survival rates. AI technologies, such as the Galleri test and Prenuvo's MRI scans, are gaining traction, with increasing adoption among physicians. The article notes the financial growth of companies like GRAIL and Prenuvo, despite initial setbacks, and emphasizes the investment opportunities in this emerging field of preventive medicine.

Forbes

iShares Global Healthcare

Global X Genomics & Biotechnology ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Bosera Hang Seng SCHK Innovative Drug Select ETF

Tema Oncology ETF

Global X Funds Global X Artificial Intelligence & Tech ETF

Tianhong CNI BIOMEDICINE ETF

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund CSI 300 Health Care ETF

China Southern Hang Seng Biotech ETF(QDII)

BlackRock, Inc.

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

GRAIL

OpenAI

How AI Could Turn Cancer Detection Into The Next Big Investment Theme

02629

Mirxes Holding Company Limited (HK:2629) is facing an ongoing trading suspension due to unresolved auditor concerns regarding significant prepayments and large cash outflows. KPMG has raised questions about the selection process for service providers and the reasonableness of contract terms. The company reported material cash outflows totaling approximately US$57 million and RMB10 million for investments and advisory fees. These issues are under review by an independent investigation committee, affecting Mirxes' governance and trading resumption conditions. The company focuses on expanding its laboratory testing and manufacturing capabilities in the life sciences sector.

MIRXES-B

E Fund CSI HK Equities Medical and Health Integration ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Mirxes Faces Ongoing Trading Suspension as Auditors Probe Prepayments and Large Cash Outflows

illumin Holdings Inc. reported its Q1 2026 financial results, with revenue rising 20% to $35.0 million, driven by a 45% increase in Exchange service revenue. Managed service revenue grew by 7%, while self-service revenue slightly declined. The gross margin decreased to 35%, and the company reported a net loss of $3.2 million. The CEO emphasized the need to balance growth with profitability and improve execution in the DSP business. The company also initiated a normal course issuer bid to repurchase shares. Cash and cash equivalents stood at $37.5 million as of March 31, 2026.

Fidelity

illumin Reports First Quarter 2026 Financial Results

Medical device company Beijing Tianxing Medical Co., Ltd. debuted on Tuesday, opening at HKD 288, up 192% from the offering price, and closing at noon up 132%. The company offered 8.422 million shares at a price of HKD 98.5 per share, raising a net amount of HKD 758 million. The public offering was oversubscribed by 7,822 times, and the international placement was oversubscribed by 9.4 times. In 2024, based on sales revenue, Tianxing Medical is the fourth largest provider of sports medicine implants and devices in China, with a market share of approximately 6.5%. Last year's revenue was HKD 403 million, an increase of 23% year-on-year; net profit was HKD 137 million, up 44% year-on-year. The funds raised will be used to expand productivity, research and development, and marketing

Hwabao WP CSI Medical Service ETF(512170.SH)